Moderna, Inc.

01 — Executive summaryA platform validation, priced as a platform victory

Moderna reported $145 million of revenue in the second quarter of 2026 and a net loss of $782 million. Both numbers are correct, and neither is the reason the shares trade where they do. On 19 August 2026, Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected stage IIB–IV cutaneous melanoma. It was the first positive Phase 3 readout for an individualised neoantigen therapy and for any mRNA-based cancer therapy, and the first trial of any kind to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant melanoma setting. Over the following two sessions the shares rose approximately 177%. They closed on 22 September 2026 at $182.56, a market capitalisation of $72.9 billion on trailing revenue of $2.23 billion.

That is the whole tension of this report. The scientific result is real, and it is more important than the market's reaction to it: it converts an entire modality from a hypothesis into a demonstrated clinical fact, and it does so in a disease where the incumbent standard of care is itself one of the most successful oncology drugs ever developed. But the equity has been re-rated from $22.28 to $182.56 in under six months, an eight-fold move, on the back of a Phase 3 interim analysis that was disclosed without hazard ratios, without a confidence interval, and without mature overall survival. The stock is now priced as though the platform has already won. Our analysis says the platform has just been validated, which is a different and much smaller claim.

The re-rating was not purely fundamental. Moderna entered 2026 as one of the most heavily shorted large-cap biotechnology companies in the market, with more than 62 million shares sold short — roughly 16% of the float — at the start of the year. When the INTerpath-001 data landed, the resulting squeeze was mechanical as well as informational; the reporting around the move put the aggregate short position at approximately $5 billion. Short interest has since fallen to 39.15 million shares, or 10.99% of the float, at 31 August 2026. A squeeze of that magnitude does not create value. It re-prices the stock faster than the fundamentals can follow, and it flatters the apparent quality of the news.

What the company actually is, as of the third quarter of 2026, is a research platform with four approved products and a collapsing commercial base. Total revenue fell from $6.85 billion in 2023 to $3.24 billion in 2024 to $1.94 billion in 2025. Management guides to growth of up to 10% in 2026, which implies approximately $2.1 billion. The company lost $2.82 billion in 2025 and $2.13 billion in the first half of 2026 alone, of which $900 million was a non-recurring litigation settlement. It holds $6.9 billion of cash, equivalents and investments as at 30 June 2026, and guides to $4.7–5.2 billion at year-end. It has committed to reaching cash breakeven in 2028. That commitment requires revenue to roughly double from the 2026 base while cash operating costs stay inside a guided 2027 range of $3.5–3.9 billion.

Our twelve-month target is $110, which is the probability-weighted output of the scenario model presented in section 24 — $21 in the bear case, $87.50 in the base case and $214 in the bull case, weighted 25/50/25 — rounded up to reflect the genuine asymmetry that a validated modality confers. That target sits below the street consensus of $119.56, and well below the market price. The direction of our divergence from the price is not contrarian: it is the same direction as the average covering analyst, and it is the same direction as Rothschild & Co Redburn, which downgraded the shares to Sell on 3 September 2026 with a price target of $81. The disagreement worth having is about magnitude, not about sign.

We are not arguing that Moderna is a broken company, and we are explicitly not arguing that the INTerpath-001 result is anything other than a major scientific achievement. We are arguing that the equity has already paid for the achievement several times over, that the commercial base beneath it is shrinking, that the reimbursement channel for new products is closed by litigation rather than by science, and that the company's own breakeven commitment implies a revenue trajectory that its four approved products are not currently producing. Those four observations are not a forecast. They are the current filing.

02 — Company and business modelOne platform, three franchises, four products

Moderna is a messenger RNA platform company. That sentence is doing more work than it appears to. The company does not describe itself as a vaccine maker, and the distinction matters for valuation: a vaccine maker is a commercial organisation with a portfolio and a manufacturing base, whereas a platform company is an organisation whose principal asset is a repeatable method for making new medicines, and whose value is therefore a function of how many modalities that method can reach. Moderna's own framing, set out at its Science Day on 25 June 2026, is that it combines three things — mRNA science, delivery science, and manufacturing process — into repeatable modalities, and that it is "preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics".

Those three franchises are at very different stages of maturity, and the difference is the substance of the investment case. The infectious disease franchise is commercialised, shrinking and subject to a hostile reimbursement environment. The intismeran franchise has just produced a positive Phase 3 and has no revenue. The rare disease franchise has one registrational programme fully enrolled and no approvals. Everything else sits in what the company calls Horizon 2 and Horizon 3: modalities in the clinic awaiting human proof of concept, and modalities that have not yet reached first-in-human trials.

The four approved products

Moderna entered 2026 with three approved products in the United States — Spikevax, the original COVID-19 vaccine; mNEXSPIKE, a next-generation COVID-19 vaccine; and mRESVIA, an RSV vaccine for older adults — and added a fourth on 5 August 2026 when the FDA approved mFLUSIVA, the first mRNA-based seasonal influenza vaccine to reach the American market. In Europe, mNEXSPIKE and the flu-plus-COVID combination product mCOMBRIAX were authorised in the first quarter of 2026, and mRESVIA has since been approved in Australia and Mexico, with mNEXSPIKE approved in Japan and Taiwan. The company's product list, in other words, is broader than its revenue base, and the gap between the two is the commercial problem.

How the company makes money

Moderna's revenue has three components, and only the first is material. Net product sales are sales of the approved vaccines to governments, distributors and, increasingly, retail pharmacy channels. Grant, collaboration and licensing revenue covers government research contracts, partnership income — principally from the Merck collaboration on intismeran autogene — and royalty receipts. Stand-ready manufacturing revenue covers capacity the company holds available for pandemic response under long-term agreements, and it is the most strategically interesting line precisely because it is the one the company cannot fully control: the US government has wound down its mRNA development funding under BARDA, while other governments have moved in the opposite direction.

In the second quarter of 2026, net product sales were $94 million and other revenue was $51 million. That composition — more than a third of revenue from non-product sources — is unusual for a commercial-stage company and is a useful diagnostic. It says that the platform is generating collaborative and contractual interest even as the commercial base contracts, and it also says that the commercial base has contracted far enough that contractual revenue has become material by default rather than by design.

The cost structure is the strategy

The single most consequential decision Moderna has made in the last two years is to shrink. On 31 July 2025 the company announced an organisational restructuring that reduced its global workforce by approximately 10%, or more than 800 employees, alongside a roughly $1.5 billion reduction in operating cost and a scaling back of research and development. At its analyst event on 20 November 2025 the company said it had discontinued four programmes, guided 2027 cash costs to $3.5–3.9 billion, and set a target of cash breakeven in 2028. At the J.P. Morgan healthcare conference on 12 January 2026 it guided 2026 GAAP operating expenses to approximately $4.9 billion, later refined at the second-quarter update to cost of sales of approximately $1.7 billion, research and development of approximately $2.9 billion and selling, general and administrative expense of approximately $1.0 billion. Headcount now stands at approximately 4,700, down from more than 5,800 at the peak.

Cutting research and development by roughly half from its 2023 peak, while simultaneously promising to bring three commercial franchises to market and to advance a pipeline of T-cell engagers and in vivo CAR-T modalities, is the central strategic bet in the equity. It is a bet that the platform has already generated more shots on goal than the company can afford to take, and that the right response is to concentrate capital on the programmes with the highest probability of technical and regulatory success. It is a defensible bet. It is also a bet that reduces the number of ways the company can surprise to the upside, and it makes the surviving programmes — intismeran above all — carry a disproportionate share of the valuation.

03 — The financial recordWhat the accounts actually show

Moderna's revenue history is the most violent in large-cap biotechnology. The company reported $18.47 billion of revenue in 2021 and $19.26 billion in 2022, at the peak of the pandemic vaccination campaign. It reported $6.85 billion in 2023, $3.24 billion in 2024 and $1.94 billion in 2025. The five-year revenue decline is 90% from the peak. Against that, the cumulative GAAP net income across the eight years from 2019 to 2026 is approximately $5.4 billion — the pandemic years still pay for everything the company has spent since, and they will continue to do so for at least another year.

The shape of that chart is worth sitting with. Moderna has never had a steady state. It went from pre-revenue to $19 billion in two years, and has spent four years coming back down. The relevant question for a valuation is not what the company earned, but whether the $19 billion of 2022 revenue was a permanent re-rating of the business or a one-time transfer of value from governments to shareholders. The answer, on the evidence of 2023 through 2026, is that it was largely the latter: the COVID-19 franchise has contracted 93% from its peak and is now a declining annuity rather than a growth business.

The quarterly pattern

Moderna's revenue is acutely seasonal and the seasonality is not cosmetic. The northern-hemisphere vaccination campaign concentrates purchasing into the third and fourth quarters, which means the second quarter of each year is structurally the weakest. In the second quarter of 2026 the company reported $145 million of revenue against $960 million of operating cost. In the first quarter it reported $389 million of revenue, of which approximately 80% came from international markets, against $1.78 billion of operating cost that included the $900 million settlement charge. Any analysis that reads a single quarter in isolation will be badly wrong in both directions depending on which quarter it picks.

The first half of 2026 is nonetheless a meaningful improvement on the first half of 2025: revenue of $534 million against $250 million, and net cash used in operations of $1.16 billion against $1.96 billion. The improvement comes from two sources. The first is that the first quarter of 2026 contained the last material deliveries under the United Kingdom long-term partnership and higher stand-ready manufacturing revenue, which lifted reported revenue well above the second quarter. The second is that the cost base is genuinely smaller: research and development fell from $1.56 billion in the first half of 2025 to $1.30 billion in the first half of 2026, and selling, general and administrative expense fell from $442 million to $389 million.

The guidance, and what it implies

Management's 2026 framework, as refined at the second-quarter update on 31 July 2026, is a target of revenue growth of up to 10% on the 2025 base — approximately $2.1 billion — split roughly evenly between the United States and international markets, with approximately 55% of second-half revenue falling in the third quarter. Cost of sales is guided to approximately $1.7 billion including the $900 million settlement, research and development to approximately $2.9 billion, selling, general and administrative expense to approximately $1.0 billion, and capital expenditure to $0.2–0.3 billion. Year-end cash and investments are guided to $4.7–5.2 billion. The company expects full year income tax expense to be negligible, which is what a company with a large accumulated loss position and a valuation allowance against its deferred tax assets should expect.

The table is the arithmetic of the whole investment case in one place. Revenue of $2.1 billion against an underlying cost base of approximately $4.7 billion, before the non-recurring settlement, is a business that consumes roughly $2.6 billion a year at the operating line before interest income. Interest income on a $6.9 billion portfolio at current short rates contributes roughly $250 million, which is why the net loss is smaller than the operating loss. Nothing in the 2026 guidance suggests the gap closes in 2026. The company's own commitment is that it closes in 2028.

What the second quarter told us that the annual accounts do not

Two details in the second-quarter disclosure are more informative than the headline loss. The first is the composition of cost of sales: $41 million of inventory write-downs, $23 million of unutilised manufacturing capacity costs and $11 million of third-party royalties, against total cost of sales of $93 million. Write-downs and idle-capacity charges together were $64 million, or 69% of the cost of the goods actually sold. That is the signature of a manufacturing base built for a pandemic and now running far below capacity, and it is why reported gross margin is a poor guide to the economics of the business at scale.

The second is the geographic mix. International revenue exceeded US revenue in the first half, and the second-quarter narrative attributed the year-on-year comparison to "lower COVID vaccine sales in the US and South America, offset by deliveries in the United Kingdom under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue." Moderna's commercial centre of gravity has moved away from the United States at exactly the moment its most valuable pipeline asset, intismeran autogene, will be launched into the US market first. That is not a contradiction, but it is a tension: the company is being carried by international and contractual revenue while its valuation rests on a US oncology launch.

04 — The 2026 re-ratingHow the shares went from $22 to $183

The single most important fact about Moderna's equity in September 2026 is that it has risen more than sevenfold in less than six months. The 52-week low of $22.28 was set in April 2026. The shares closed on 22 September 2026 at $182.56. Market capitalisation has risen 642% over twelve months. Nothing about the underlying business changed by a comparable amount: revenue is guided to grow by at most 10%, the company still expects to lose money in 2026, and its breakeven target is two years away.

The move had four identifiable drivers, and they are worth separating because they have different persistence.

The correct reading of the sequence is that the science is real, the squeeze is real, and they are not the same thing. The Phase 3 result justifies a substantial increase in the value of the intismeran programme — our own model values it at $12.4 billion risk-adjusted, the largest single component of the sum of parts. It does not justify a $38 billion gap between the risk-adjusted value of the entire company and its market capitalisation. The market has, in effect, applied the probability of success of a de-risked asset to a portfolio that is mostly not de-risked.

The analyst community has not followed the price

According to consensus data compiled across 23 covering analysts, the average rating on Moderna is Hold and the average twelve-month price target is $119.56, which is 34.5% below the 22 September close. On 3 September 2026 Rothschild & Co Redburn downgraded the shares from Neutral to Sell, raising its target from $40 to $81 — a 46.3% discount to the $150.81 price at the time of the note. The pattern is unusual. Normally a large re-rating drags targets upward within days. Here, targets have risen but not remotely to the level of the price, and the dispersion has widened rather than narrowed. That is what happens when a move is driven by positioning rather than by a change in modelled cash flows.

05 — Quality of earningsReported margin, and the margin underneath

Moderna's reported gross margin is close to meaningless as a measure of the underlying business, and understanding why is a prerequisite for understanding the valuation. The reported figure is total revenue less cost of sales, divided by total revenue. In 2021 and 2022 that was approximately 95% and 71%. In 2023 it collapsed to 37.1% as demand fell and the company wrote down inventory manufactured against pandemic forecasts. In 2024 it recovered to 64.7%. In 2025 it fell to 25.4%. In 2026 it is guided to approximately 19.0%, distorted by the $900 million settlement booked into cost of sales.

Strip out the three items that are not really costs of goods — inventory write-downs, unutilised manufacturing capacity charges and the one-off settlement — and the picture is materially different. On our estimates the underlying margin was approximately 42% in 2023, 68% in 2024, 30% in 2025 and 61.9% in 2026. The underlying margin in 2025 was depressed by idle capacity charges against a much smaller revenue base; the underlying margin in 2026 benefits from the settlement being excluded, but also from the fact that the remaining revenue mix is weighted toward higher-priced international government contracts and stand-ready manufacturing arrangements.

Three items to watch in the earnings quality

First, the litigation settlement is a real cash cost and a non-recurring accounting one. The Arbutus/Genevant settlement was charged to cost of sales in the first quarter of 2026 at approximately $900 million and paid in July 2026 at $950 million. Analysts who exclude it from a 2026 margin calculation are right to do so, and analysts who exclude it from a cash-flow analysis are wrong, because the cash left the building. What almost nobody has priced is the second tranche: the settlement carries a further $1.3 billion of contingent consideration payable if Moderna loses its Section 1498 appeal, which is discussed in section 19.

Second, stand-ready manufacturing and collaboration revenue is lower quality than product revenue. In the second quarter, $51 million of the $145 million of reported revenue came from grant, collaboration, licensing, royalty and stand-ready manufacturing sources. This revenue is contractual and therefore visible, but it is not repeatable in the way product sales are, and it carries different margins. It also has a strategic character: the UK partnership and the European Commission joint procurement for up to 24 million doses of mRESVIA are evidence that governments outside the United States are still willing to contract with Moderna at scale, which is the most important counterweight to the US policy position described in section 18.

Third, the tax line is not a signal of profitability. The company expects negligible full-year 2026 income tax expense, and reported a $15 million provision in the second quarter against a $767 million pre-tax loss. With a large accumulated deficit and a valuation allowance against deferred tax assets, a negligible tax line tells you nothing about earnings power. It does tell you that a future return to profitability would not be taxed immediately, which is a modest and underappreciated asset.

Cash flow versus earnings

The gap between Moderna's net loss and its operating cash consumption narrowed materially in the first half of 2026. Net cash used in operating activities was $1.16 billion against a net loss of $2.13 billion, a difference of approximately $0.97 billion, which is mostly the non-cash settlement accrual, share-based compensation, depreciation and the working-capital swing that accompanies the seasonal build of inventory ahead of the autumn campaign. In the first half of 2025 the equivalent figures were $1.96 billion of operating cash use against a $1.80 billion net loss, a much smaller gap. The improvement in cash conversion is real and reflects tighter inventory management and a smaller cost base.

It is important not to over-read this. A company that loses $2.1 billion in six months and consumes $1.2 billion of cash is still consuming cash at a rate of roughly $2.4 billion a year, and its year-end cash balance is guided to $4.7–5.2 billion against $8.14 billion at the end of 2025. The burn is smaller than it was. It has not stopped.

06 — Cost structure and the restructuringThe company that decided to shrink

Moderna's operating cost base peaked at approximately $10.3 billion in 2023, when research and development alone was $4.82 billion and cost of sales was $4.31 billion against $6.85 billion of revenue. The company was spending more than it earned, on a cost base built for a pandemic that had ended. The restructuring announced on 31 July 2025 was the admission, and the numbers since are the execution.

Research and development has fallen from $4.82 billion in 2023 to an estimated $2.90 billion in 2026 — a 40% reduction in three years, and a 48% reduction from the peak. Cost of sales has fallen from $4.31 billion to a guided $1.70 billion, although roughly half of the 2026 figure is the one-off settlement. Selling, general and administrative expense has fallen from $1.28 billion in 2024 to approximately $1.00 billion in 2026, with the small increase over 2025 reflecting the commercial build for mFLUSIVA and mCOMBRIAX. Total operating cost is guided to approximately $5.6 billion in 2026, of which approximately $4.7 billion is the underlying run rate.

Management has guided 2027 cash costs to $3.5–3.9 billion, which would represent a further reduction of roughly $0.8–1.2 billion from the 2026 underlying level. That is a substantial additional cut, and it is the single most important number in the company's path to breakeven. If 2027 cash costs land at $3.7 billion, the mid-point of guidance, then breakeven in 2028 requires revenue of approximately $3.7–4.0 billion depending on gross margin — roughly double the guided 2026 revenue, delivered in two years, from a base that has been declining for four.

What was cut, and what was protected

The company disclosed that it discontinued four programmes in the November 2025 restructuring. It has not disclosed all four, but the pattern of what has been protected is clear from the Science Day materials and the pipeline disclosures. Intismeran autogene has been protected and expanded — nine Phase 2 and Phase 3 trials are running across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. The rare disease programmes in propionic acidemia and methylmalonic acidemia have been protected, with the propionic acidemia registrational study reaching target enrolment. The T-cell engager modality has been protected, with mRNA-2808 in multiple myeloma and mRNA-2151 planned in ovarian cancer. What was cut was largely the long tail: programmes without a near-term registrational path, and the breadth of the earlier-stage infectious disease portfolio.

That is a rational allocation. It is also a concentration of risk. A company that has cut research and development by half and is running its remaining spend through nine trials of a single asset has, in a meaningful sense, become a single-asset company with a vaccine business attached. The valuation in section 23 reflects that: intismeran autogene alone is 36% of the risk-adjusted sum of parts, and 42% if net cash is excluded.

Share-based compensation and the real cost base

Moderna's cost reduction has been achieved against a headcount that has fallen from more than 5,800 to approximately 4,700, a reduction of roughly 19% against a 40% cut in research and development expense. The difference is explained partly by the mix — the company cut programmes rather than people proportionately, and it protected the teams working on its highest-value assets — and partly by share-based compensation, which is a real cost that does not leave the bank account in the year it is recognised. Any analysis of the company's cash breakeven should note that a return to profitability on a GAAP basis will lag the cash milestone, because the compensation expense is recognised as the equity vests.

07 — The COVID franchiseThe annuity nobody wants to talk about

Moderna's COVID-19 vaccine business peaked at $18.4 billion of product sales in 2022. On our estimates it will generate approximately $1.35 billion in 2026 — a decline of 93% in four years. The franchise is now smaller than the company's annual research and development budget, and it is still the largest single source of revenue in the business.

The decline has three causes and they are worth separating, because they have different futures. The first is epidemiological: population-level immunity from infection and vaccination is broad, the virus has settled into a seasonal pattern with a lower severity profile, and the clinical rationale for universal annual boosting has weakened. The second is competitive: Moderna shares the market with Pfizer and BioNTech, with Novavax in a distant third position, and the competitive dynamic in a shrinking market is price and contracting rather than efficacy. The third, and the most important for anyone modelling a floor, is policy: the US recommendation environment has changed in a way that directly reduces the addressable population and removes the first-dollar coverage that made the product frictionless at the pharmacy counter.

There is a counter-argument, and it deserves a fair hearing. Moderna's international business has held up better than its US business. The first quarter of 2026 was approximately 80% international, the United Kingdom long-term partnership produced material deliveries, and the European Commission signed a joint procurement contract on behalf of six countries for up to 24 million doses of mRESVIA. Governments outside the United States continue to contract for respiratory vaccines on multi-year terms, and they are less exposed to the specific litigation that has frozen the US advisory process. The United States is the largest single market for vaccines and it is the market where Moderna's position has deteriorated fastest.

mNEXSPIKE and the product refresh

Moderna's answer to the declining COVID franchise has been to refresh the product. mNEXSPIKE is a next-generation COVID-19 vaccine that was approved in the United States and subsequently in Europe, Japan and Taiwan. The commercial logic is that a differentiated formulation can hold price and share in a contracting market. The financial evidence for that thesis is not yet available: the company reports COVID-19 vaccine product sales as a single line and does not break out Spikevax from mNEXSPIKE. Until it does, any claim about the success of the product refresh is a claim about a regulatory milestone rather than a commercial one.

What can be said is that the vaccine market rewards incumbency and institutional contracting, not novelty. In a market where the buying decision is made by a national immunisation programme once a year, a new formulation wins share only if it is either materially more effective or materially cheaper to deliver. Moderna has not published a head-to-head efficacy advantage for mNEXSPIKE over Spikevax in a form that would support a premium price, and the company's own disclosure frames the product as a multi-year revenue growth strategy rather than as a share-taking event.

08 — RSV, influenza and combination vaccinesThree products, one strategy

Moderna's respiratory strategy outside COVID-19 has three components: mRESVIA in RSV, mFLUSIVA in seasonal influenza, and mCOMBRIAX as the flu-plus-COVID combination that turns two injections into one. They are not independent bets. The combination product is the strategic destination and the two monovalent products are the regulatory and commercial stepping stones toward it. Understanding that structure is essential, because it means the flu franchise should be valued on the combination product's economics rather than on the flu vaccine's own market share.

mFLUSIVA: a real but modest edge

The FDA approved mFLUSIVA on 5 August 2026, following a unanimous 9–0 recommendation from the Vaccines and Related Biological Products Advisory Committee on 18 June 2026. The approval is bifurcated in a way that matters commercially. For adults aged 50 to 64 it is a full approval based on clinical efficacy endpoints. For adults aged 65 and over it is an accelerated approval based on haemagglutination-inhibition geometric mean titres and seroconversion rates as surrogate endpoints, conditioned on a Phase 4 confirmatory trial demonstrating non-inferiority against licensed high-dose influenza vaccines. The product is not approved for adults under 50.

The clinical data come from the Phase 3 P304 trial, which enrolled 40,703 adults aged 50 and over and accrued 968 laboratory-confirmed influenza cases across the 2024–25 northern and southern hemisphere seasons. Against a standard-dose comparator, overall relative vaccine efficacy was 26.6% with a 95% confidence interval of 16.7% to 35.4%, meeting the pre-specified success criterion that required the lower bound to exceed 9%. Relative efficacy was 25.8% in adults aged 50–64 and 27.4% in adults aged 65 and over. By strain, efficacy was 29.6% against A/H1N1, 22.2% against A/H3N2 and 29.1% against B/Victoria. The healthcare-outcome endpoint — a composite of emergency department visits, hospitalisations and urgent care encounters — showed a relative reduction of 47.9%, which is the number that matters most for payer conversations and the number least likely to be reproduced exactly in a second trial.

Two caveats belong next to those figures. First, the comparator was standard-dose influenza vaccine, not the enhanced products — Fluzone High-Dose Quadrivalent and Fluad Adjuvanted — that dominate the 65-and-over segment and that historically deliver relative efficacy of roughly 24% against standard dose. mFLUSIVA's 27.4% in the 65-plus cohort is therefore suggestive of comparability with, not superiority over, the products it must displace in the most valuable part of the market, and the Phase 4 commitment exists precisely because that comparison has not been made. Second, reactogenicity is higher than standard dose: injection site pain was reported by 68.4% of recipients against 34.1% for the comparator, fatigue by 42.1%, and myalgia by 38.7%, with Grade 3 adverse events at 2.8% against 1.1%, resolving within a median of 48 hours. In a market where the product is administered to tens of millions of healthy older adults, tolerability is a commercial variable, not a footnote.

mCOMBRIAX and the second act

The combination product is the point of the exercise. mRNA-1083, marketed in Europe as mCOMBRIAX, combines seasonal influenza and COVID-19 in a single injection. It received European marketing authorisation in the first quarter of 2026, alongside mNEXSPIKE, and filings are under review in Japan, Canada and Australia. The US position is more complicated: Moderna submitted a biologics licence application, the FDA requested additional data, and the company voluntarily withdrew the application in May 2025. A US refiling depends on FDA guidance that had not been issued as at our data cut-off.

The commercial logic of a combination vaccine is straightforward and it is the reason this programme carries more value in our model than mFLUSIVA alone. One injection instead of two raises realised price per administration while reducing delivery cost, it improves coverage in the portion of the population that would otherwise receive only one of the two products, and it converts Moderna from a supplier of one vaccine into a supplier of the seasonal respiratory appointment. Jefferies analysts have estimated that mFLUSIVA and its combination derivative could generate more than $750 million of annual US sales by 2030. Our base case is more conservative than that in the near term and more ambitious in the long term, because we think the combination product, not the monovalent one, is where the franchise value sits.

mRESVIA: the quiet disappointment

mRESVIA was approved in the United States in 2024 and has since been approved in Australia and Mexico, with a European Commission joint procurement contract covering up to 24 million doses for six countries. It is Moderna's third product and it has never been commercially material. The RSV vaccine market is dominated by GSK's Arexvy and Pfizer's Abrysvo, both of which reached the market first and both of which have established positions in the pharmacy and long-term care channels that matter. Moderna's product has a differentiated profile in one respect — it is the only RSV vaccine in the US market supplied in a pre-filled syringe — and that is a convenience advantage rather than an efficacy advantage.

We value mRESVIA at $1.6 billion of risk-adjusted value, the smallest material component of the sum of parts. That reflects a realistic assessment: a third entrant into a two-player market, with a modest differentiation, in a category where the addressable population is large but the purchasing decision is concentrated and the incumbent relationships are entrenched. The European procurement contract is the most valuable part of the asset, because it converts a commercial competition into a contracted volume.

09 — International and government channelsThe revenue that is holding the company up

The most under-discussed fact in Moderna's recent disclosure is that the United States is no longer its largest market. In the first quarter of 2026 approximately 80% of revenue came from outside the United States. In the second quarter the split was $87 million domestic against $58 million international, and the year-on-year comparison was explained by the company as "lower COVID vaccine sales in the US and South America, offset by deliveries in the United Kingdom under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue." The second quarter is the one quarter where the US mix is normally flattered, because the domestic autumn contracting season has not yet begun, and even there the domestic business was only 60% of the total.

This matters for three reasons. First, it means the revenue base that remains is more durable than a US-only read would suggest, because it is contracted rather than competed. Second, it means the reported revenue line is less sensitive to the specific US reimbursement problem discussed in section 18 than the headline suggests. Third, and least comfortably, it means that the company's commercial centre of gravity has moved away from the market in which its most valuable pipeline asset will be launched first. Intismeran autogene will be filed and commercialised in the United States before anywhere else, because that is where the adjuvant melanoma standard of care — KEYTRUDA — is most deeply entrenched and where the clinical trial population was accrued. A company whose revenue is 60–80% international is building its valuation on a domestic oncology launch.

The chart above is the honest starting point for any franchise-level discussion, because it distinguishes between the size of a market and the size of Moderna's opportunity inside it. The global COVID-19 vaccine market is now roughly $5 billion a year and shrinking. Seasonal influenza is larger, at approximately $7 billion, and structurally more attractive because it is an annual repurchase with a stable, non-pandemic-driven demand base of around 600 million doses globally. RSV in older adults is a $3 billion market that two well-entrenched incumbents have already divided. Adjuvant melanoma — the indication where intismeran has just succeeded — is a comparatively small pool at around $2.6 billion, which is precisely why the programme's value depends on the other indications in the nine-trial programme rather than on melanoma itself.

What the government partnerships actually are

Moderna has signed long-term strategic partnerships with the United Kingdom, Canada and Australia, each of which pairs a multi-year supply commitment with a domestic manufacturing facility: Laval in Quebec, Harwell in Oxfordshire, and Clayton in Victoria. These are not ordinary commercial contracts. They are industrial-policy instruments in which the sovereign counterparty obtains domestic mRNA manufacturing capacity and priority access in a future pandemic, and Moderna obtains revenue visibility, capital contribution and a political constituency.

The economics are deliberately opaque. Moderna has not disclosed the contract values, the minimum volumes or the pricing. What it has disclosed is that the partnerships are a 2026 revenue growth driver through "the annualized impact of long-term partnerships in the UK, Canada and Australia," and that they were a material contributor to the first quarter. The UK partnership in particular produced the deliveries that made the first quarter of 2026 look far better than the second. For an analyst, this creates a genuine estimation problem: a meaningful share of the revenue base is contracted, visible in aggregate, and unmodelled in detail.

There is also a pandemic-preparedness channel that is worth more than its current revenue. The Coalition for Epidemic Preparedness Innovations agreed in January 2026 to invest up to $54.3 million to support a pivotal Phase 3 trial of mRNA-1018, Moderna's H5 pandemic influenza candidate, toward licensure. That is a small number, but it is a strategically significant one: it means that at least one supranational body is still willing to fund Moderna's mRNA platform for pandemic response at a moment when the US government has moved in the opposite direction. Stand-ready manufacturing revenue — capacity held available under long-term agreements — is the accounting expression of that willingness, and it was a contributor to the second quarter's revenue composition.

The counter-argument is that contractual revenue is lower quality than product revenue. It is visible, but it is not repeatable in the way a consumer product is, it carries different margins, and it is renewed at the discretion of a small number of government buyers. In the second quarter, $51 million of the $145 million of reported revenue came from grant, collaboration, licensing, royalty and stand-ready manufacturing sources. That is 35% of revenue from non-product sources. For a company that describes itself as commercial-stage, it is an unusually high proportion, and it is high because the product business has shrunk beneath it rather than because the contractual business has grown.

10 — Intismeran autogeneWhat the Phase 3 proves, and what it does not

Intismeran autogene — mRNA-4157, V940 — is the asset on which this entire equity now turns. It is an individualised neoantigen therapy: the patient's tumour is sequenced, up to 34 neoantigens are selected by algorithm, and a bespoke mRNA construct encoding those neoantigens is manufactured for that patient alone and administered with Merck's KEYTRUDA. It is partnered 50/50 with Merck on cost and profit. It is the first such product to produce a positive Phase 3 readout, and it is the reason the shares trade where they do.

On 19 August 2026 the two companies announced that INTerpath-001, the Phase 3 trial in completely resected stage IIB–IV cutaneous melanoma, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis. The safety profile was consistent with prior studies and no new signals were reported. The trial will continue to evaluate overall survival, and the data will be presented at a medical meeting and shared with regulators. The shares rose approximately 177% over two sessions.

What the announcement did not contain is as important as what it did. No hazard ratio. No confidence interval. No p-value. No absolute difference in recurrence-free survival at a stated time point. No subgroup analysis. No median follow-up. No statement of whether the interim analysis was for efficacy or futility, or whether the boundary crossed was the pre-specified one or a secondary one. This is not a criticism of the companies: an interim topline release is a regulatory and competitive necessity, and the full data belong at a medical meeting. But it means that every quantitative estimate of intismeran's commercial value, including ours, is being built on an effect size that has not been disclosed.

Why the melanoma result matters more than melanoma

Adjuvant cutaneous melanoma is a small market — our estimate of the relevant pool is approximately $2.6 billion a year — and Moderna receives half of the profit. A product that captured a third of that pool would generate something under $450 million of annual revenue to the partnership, or a little over $200 million to Moderna. That is not a $12 billion risk-adjusted asset, and it is not why the stock went up sevenfold.

The value is in what the result implies about the modality. An individualised neoantigen therapy that works in adjuvant melanoma establishes three things at once: that mRNA can be manufactured at scale for a single patient, that a neoantigen selection algorithm can pick targets that a T-cell response can act on, and that adding such a therapy to a PD-1 inhibitor produces a clinical benefit large enough to be detected in a randomised Phase 3. If those three propositions hold, they hold for the other eight trials in the programme — non-small cell lung cancer, bladder cancer, renal cell carcinoma, and the monotherapy setting — and they hold for a much larger addressable pool. That is the legitimate bull case, and it is a strong one.

Our own modelling, shown above, puts the base case at approximately $3.9 billion of gross revenue by 2033, with the bull case at $8.2 billion and the bear case at $1.0 billion. Those figures are gross, before Merck's profit share. They imply a risk-adjusted value to Moderna of $12.4 billion, which is the largest single component of our sum of parts and 36% of it. We have applied a 78% probability of success conditional on the Phase 3 readout — high, because the readout has happened and the regulatory path is now clear — and a discount rate of 11%.

There is one further asymmetry that deserves stating. The Phase 3 readout was a success, and the market repriced the whole company. But the trial continues to evaluate overall survival, and overall survival in an adjuvant setting takes years to mature. That means the next material readout on the most valuable asset in the company is not imminent, and the interim that moved the stock is not the last word on the drug. Between now and the overall survival data, the equity is trading on a hazard ratio that has not been published.

11 — Oncology beyond melanomaNine trials, one asset, and the pipeline behind it

The intismeran programme is not one trial. It is nine Phase 2 and Phase 3 studies across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, including a Phase 3 in high-risk stage 1 NSCLC as monotherapy and in combination with KEYTRUDA QLEX. Four of those studies are fully enrolled: the Phase 3 adjuvant melanoma trial, a Phase 2 adjuvant renal cell carcinoma trial, a Phase 2 adjuvant muscle-invasive bladder cancer trial, and the monotherapy study. The company has said it targets readouts from the nine studies and describes three Phase 3 programmes for intismeran specifically.

The significance of the breadth is that the melanoma result, if it generalises, is a template rather than a product. Adjuvant renal cell carcinoma and muscle-invasive bladder cancer are both settings where a PD-1 inhibitor is standard and where recurrence rates remain high — the two structural preconditions for an adjuvant neoantigen therapy to add value. NSCLC is the largest pool of the four and the hardest, because the standard of care is more complex and the patient population more heterogeneous.

Beyond intismeran, Moderna's oncology portfolio is earlier and wholly owned, which is both the opportunity and the risk. mRNA-4359, a cancer antigen therapy designed to elicit T-cell responses against both tumour and immunosuppressive cells, is in a Phase 1/2 study whose Phase 2 portion includes cohorts in first-line metastatic melanoma, second-line and later metastatic melanoma, and first-line metastatic NSCLC. A potential Phase 2 readout was expected in 2026. Because it is wholly owned, a positive result accrues entirely to Moderna rather than being shared with Merck, which makes it the single most important wholly-owned oncology asset in the portfolio.

The earlier-stage oncology programmes introduced at Science Day in June 2026 fall into two families. The first is shared-antigen therapies — mRNA-4106, encoding non-mutated cancer-testis antigens, in a Phase 1 monotherapy study in advanced solid tumours; and mRNA-4200, encoding shared tumour-associated antigens, with a Phase 1 planned in combination with pembrolizumab. These are off-the-shelf products, which is the important distinction: unlike intismeran they do not require per-patient manufacturing, so they scale in the way a conventional biologic does. The second is cancer prevention. mRNA-4194 encodes frameshift peptides frequently identified in Lynch syndrome, and a Phase 1/2 study was planned to begin in the summer of 2026 with the explicit goal of preventing progression of pre-malignancies to cancer. It is Moderna's first investigational cancer prevention programme, and if the concept works it is a far larger idea than any treatment in the portfolio.

12 — Rare disease therapeuticsThe franchise with no revenue and a real readout

Rare disease is the third of the three commercial franchises Moderna says it is preparing to manage, and it is the one with the least to show. The lead asset is mRNA-3927, a therapeutic for propionic acidemia — a rare inherited metabolic disorder in which the body cannot process certain amino acids, causing recurrent life-threatening metabolic crises. It is delivered as an mRNA therapeutic rather than a vaccine, which makes it a genuinely different test of the platform: it is the first clinical programme to report results for an mRNA therapeutic for intracellular protein replacement, and its Phase 1/2 interim data were published in Nature in 2024.

The registrational study has reached target enrolment and the company expects a data readout. The second programme, mRNA-3705 for methylmalonic acidemia, was selected for the FDA's START pilot programme for rare disease therapeutics and a registrational study had been expected to begin in 2026; at the second-quarter update the company deferred the pivotal-trial decision until the propionic acidemia registrational data read out. That deferral is a rational use of a constrained budget, and it is also an admission that the rare disease franchise is being sequenced rather than run in parallel.

The commercial logic of rare disease therapeutics is attractive in the abstract: small patient populations, high prices, limited competition, and a regulatory environment that rewards innovation with expedited pathways. It is also unforgiving in practice. These are chronic, potentially lifelong therapies in severely ill children, which means the safety bar is high, the manufacturing must be reliable at small scale, and the reimbursement conversation is with a small number of specialised payers who are experienced at negotiating orphan pricing. A single negative safety signal in a paediatric metabolic population would be disproportionately damaging to the platform's therapeutic credibility.

We value the rare disease franchise at $2.7 billion of risk-adjusted value, which makes it the third-largest component of the sum of parts despite having no revenue, no approval and no disclosed efficacy data beyond Phase 1/2. That is a statement about the option value of a validated mRNA therapeutic modality rather than a statement about propionic acidemia. If the registrational data are positive, the franchise re-rates; if they are negative, the mRNA-as-therapeutic thesis — as distinct from mRNA-as-vaccine — loses its only advanced test, and the $2.7 billion comes out of the model with nothing to replace it.

13 — Horizon 2 and Horizon 3Paying for optionality with a shrinking budget

Moderna organises its pipeline into three horizons, and the framing is genuinely useful because it separates assets by the kind of evidence that exists for them rather than by their position in a queue. Horizon 1 comprises the established modalities: infectious disease vaccines, intismeran autogene, and rare disease therapeutics — the late-stage and approved products. Horizon 2 comprises modalities that are in the clinic and awaiting human proof of concept, the majority in Phase 1/2 oncology studies, with one multiple sclerosis therapeutic in Phase 2. Horizon 3 comprises modalities with the potential to reach first-in-human trials by the end of 2027.

The two named Horizon 2 modalities are T-cell engagers and the shared-antigen cancer therapies. mRNA-2808 is a multiplexed T-cell engager in a Phase 1/2 study in multiple myeloma, carrying three distinct engagers against clinically validated targets, and the company describes an encouraging early clinical signal that supports the advancement of a second programme, mRNA-2151, in ovarian cancer. mRNA-1195 is a therapeutic for Epstein-Barr-virus-associated conditions including multiple sclerosis; Phase 1 part B data were expected in the second half of 2026, and the Phase 2 study in multiple sclerosis is ongoing with its sentinel cohort fully enrolled and a data safety monitoring board recommendation to proceed with dose escalation.

Horizon 3 is where the platform argument is at its most ambitious and its least evidenced. mRNA-6007 is an in vivo CAR-T programme: rather than extracting a patient's T-cells, engineering them and reinfusing them, it aims to deliver mRNA into immune cells inside the body using targeted lipid nanoparticles, producing transient CAR expression and what the company calls a potential immune reset. The initial clinical focus is systemic lupus erythematosus and other B-cell-mediated autoimmune diseases. If it works, it addresses one of the most commercially attractive and technically crowded areas in medicine — the ex vivo CAR-T companies have shown the efficacy and are constrained by cost, logistics and tolerability, all three of which an in vivo approach could plausibly improve.

14 — CompetitionFour markets, four different problems

Moderna competes in four markets and the nature of the competition is different in each. In COVID-19 vaccines it is a share fight in a shrinking pool against a better-capitalised incumbent. In seasonal influenza it is a new entrant against a mature oligopoly with entrenched contracts and enhanced products. In RSV it is a third entrant against two first-movers. In oncology it is a modality leader in a field where the incumbents are among the most successful drugs ever developed.

COVID-19: a two-player market with a third seat

The COVID-19 mRNA vaccine market is effectively a duopoly between Moderna and the Pfizer/BioNTech combination, with Novavax in a distant third position using a protein subunit approach. The relative scale is stark: in its own litigation disclosure, Arbutus noted that Comirnaty sales represent approximately two thirds of global COVID-mRNA vaccine sales to date. Moderna is the smaller of the two by a wide margin, in a market that has contracted by roughly 90% from its peak, competing on price and contracting rather than on efficacy. That is an unattractive structural position, and no amount of product refreshment changes it. The one genuine advantage Moderna holds is that its next-generation construct, mNEXSPIKE, is approved and differentiated in formulation; the company has not published a head-to-head efficacy advantage in a form that would support a premium price, and the market's annual purchasing decision is made by national immunisation programmes that reward incumbency.

Influenza: the hardest market in vaccines

Seasonal influenza is a $7 billion market with roughly 600 million doses administered globally each year, and it is dominated by an oligopoly — Sanofi, CSL Seqirus and GSK — with decades of manufacturing relationships, established distribution and, critically, the enhanced products that occupy the most valuable segment. In the 65-and-over population, Fluzone High-Dose Quadrivalent and Fluad Adjuvanted have historically delivered relative efficacy of roughly 24% against standard dose, and they are what physicians and payers already use.

mFLUSIVA's Phase 3 data, discussed in section 08, show 26.6% overall relative efficacy against a standard-dose comparator and 27.4% in the 65-plus cohort. That is a real result and it is consistent with the enhanced products — but it is a comparison against the wrong comparator for the segment that matters most, which is exactly why the FDA's accelerated approval in the 65-plus population is conditioned on a Phase 4 confirmatory trial demonstrating non-inferiority against licensed high-dose influenza vaccines. Moderna's commercial case in influenza rests on a trial that has not yet been run.

RSV: third entrant, differentiated by format

mRESVIA competes with GSK's Arexvy and Pfizer's Abrysvo, both of which reached the market first and both of which have established positions in the pharmacy and long-term care channels. Moderna's product has one genuine point of differentiation — it is supplied in a pre-filled syringe, the only RSV vaccine in the US market to be — and that is a convenience advantage rather than an efficacy advantage. In a market where the purchasing decision is concentrated among a small number of institutional buyers and the incumbents have already signed their contracts, a format advantage is worth something but not much. The European Commission joint procurement contract for up to 24 million doses across six countries is the most valuable part of the asset precisely because it sidesteps the commercial competition entirely.

In oncology the competitive picture is genuinely different, and it is the one place where Moderna's position is a lead rather than a deficit. It is the first company to produce a positive Phase 3 for an individualised neoantigen therapy, ahead of BioNTech's competing programmes. That lead is real and it is worth paying something for. But oncology is also the market where the bar is highest, because the standard of care against which an adjuvant therapy must be added is KEYTRUDA — one of the most successful drugs ever developed — and because a personalised manufacturing model must be proved commercially, not just clinically.

15 — Balance sheet and liquidityA fortress that is being spent

The balance sheet is the single strongest argument for owning Moderna, and it is also the cleanest way to see the time constraint under which the company is operating. At 30 June 2026 Moderna held $6.9 billion of cash, cash equivalents and investments, comprising $1.72 billion of cash and equivalents, $3.42 billion of current investments and $1.77 billion of non-current investments. Against that it carries $591 million of long-term debt, which is the amount drawn under a five-year term loan facility of up to $1.5 billion arranged with Ares Management Credit Funds and closed in November 2025. The facility is non-dilutive, which is the reason it exists, and $0.9 billion of it remains undrawn.

Total assets were $10.96 billion at 30 June 2026, down from $12.34 billion at the end of 2025. Total liabilities were $4.20 billion and stockholders' equity was $6.76 billion, down from $8.65 billion at year-end 2025. Retained earnings have fallen from $7.22 billion to $5.10 billion in six months. The company is, in the strict accounting sense, consuming its accumulated pandemic profits — and it is doing so at a rate of roughly $1.2 billion per half-year on the cash flow statement, against a $2.1 billion GAAP loss on the income statement.

The bridge above is worth reading closely, because it separates three things that are often conflated. The first is the operating burn, which was $1.16 billion in the first half. The second is capital expenditure, which was only $99 million in the first half against a full year guidance of $0.2–0.3 billion — the company has stopped building. The third is the litigation settlement, which is a single $950 million payment made in July 2026 and which does not recur. Our estimate of the year-end position, $4.82 billion, sits inside the guided range of $4.7–5.2 billion and is derived by applying the company's own guided operating envelope to the second half.

There is one further claim on the balance sheet that is not on it. The Arbutus/Genevant settlement, described in section 19, carries a $1.3 billion contingent payment that becomes due if Moderna loses its Section 1498 appeal. It is not accrued because the outcome is genuinely uncertain, but it is a real contingent liability and it is material relative to a $4.8 billion guided year-end cash balance. A company with $6.9 billion of cash and a $1.3 billion contingent patent liability has $5.6 billion of cash in the bad state of the world.

What the balance sheet buys, and what it does not

The bull case for the balance sheet is straightforward and largely correct. Moderna has no meaningful debt maturity wall, a non-dilutive facility with $0.9 billion undrawn, a negligible tax expense because of its accumulated deficit and valuation allowance, and enough liquidity to fund the guided cost base for several years even with no revenue improvement. Management's own statement is that the balance sheet "sufficiently funds its investments through targeted cash breakeven in 2028," and on the guided numbers that assertion holds.

The bear case is that a balance sheet is a duration, not a destination. $4.8 billion of year-end cash against an underlying annual cash cost base of approximately $4.7 billion is roughly one year of operating expense in liquid form, before any revenue. That is adequate but it is not a fortress, and the entire construction depends on the respiratory franchise not deteriorating further and on intismeran launching on something close to schedule. Our bear case in section 24 — in which the respiratory business flatlines, intismeran slips to 2029 and cash costs stay at the top of the guided range — exhausts the liquidity in 2029 without any equity issuance. That is not a prediction. It is the arithmetic that would force a dilutive financing at the worst possible moment, and it is the largest fundamental risk in the equity.

16 — Cash burn and runwayBetter than it was, still not fixed

Moderna's cash consumption has improved materially and the improvement is real, but it has been achieved by shrinking the business rather than by growing it. Net cash used in operating activities was $1.16 billion in the first half of 2026 against $1.96 billion in the first half of 2025, a 41% reduction. In the same period revenue rose from $250 million to $534 million and research and development expense fell from $1.56 billion to $1.30 billion. Both sides of the ledger moved in the right direction; only one of them is sustainable.

The quarterly pattern in the chart above is dominated by seasonality, and reading a single quarter in isolation will mislead in either direction. Cash collections follow the northern-hemisphere vaccination campaign, which means the third and fourth quarters are the strongest and the second quarter is structurally the weakest. The second quarter of 2026 consumed $556 million of operating cash against $145 million of revenue — a ratio that looks catastrophic and is simply the arithmetic of a seasonal business with a fixed cost base. What matters is the annual total: approximately $2.4 billion of operating cash consumption in 2026 on our estimates, against $2.9 billion in 2025.

The runway chart is the most important forward-looking exhibit in this report, because it isolates the single variable that determines whether the equity is a financing story or an operating story. In our base case — revenue compounding at roughly 18% a year from the 2026 base, cash operating costs held at the low end of the guided 2027 range, and intismeran launching in 2027 — liquidity dips to approximately $3.1 billion at the end of 2028 and then stabilises, which is what a company that reaches cash breakeven in 2028 looks like. In the bear case — the respiratory business flatlines, intismeran slips to 2029, and cash costs stay near the top of the guided range — liquidity falls below $2 billion by the end of 2027 and is exhausted in 2029.

The 2028 breakeven, taken seriously

Moderna's commitment is to reach cash breakeven in 2028. It is worth testing that commitment against the company's own guidance rather than against a bull case. The starting point is revenue of approximately $2.1 billion in 2026 and cash costs of $3.5–3.9 billion in 2027. Taking the mid-point of $3.7 billion and a gross margin of 60%, breakeven requires approximately $3.7 billion of revenue in 2028. Compounding the 2026 base at 18% a year produces $2.9 billion — short by roughly $0.8 billion. Reaching $3.7 billion in two years requires growth of approximately 33% a year, which is more than three times the growth rate the company has guided for 2026.

That is not an argument that the target is unreachable. A successful intismeran launch, a flu-plus-COVID combination that takes share from incumbent adjuvanted products, and a norovirus vaccine would together produce growth well above 33%. It is an argument that the breakeven target is not a base case — it is an outcome that requires at least one of the company's unlaunched products to succeed commercially, and the market is currently pricing it as though it were certain. The company has described the target as a commitment rather than a forecast, which is the honest framing, and we have modelled it that way.

17 — Manufacturing and the networkThe asset that has to be right-scaled

Moderna's manufacturing footprint is the least visible and most consequential part of its transition, because it is where the difference between a 20% gross margin and a 70% gross margin is determined. Since 2022 the company has consolidated from a pandemic-era network into a smaller set of owned and operated sites, exiting eight contract manufacturers and adding three Moderna-built facilities in Laval, Harwell and Clayton to serve the Canadian, UK and Australian partnerships. In the United States the Norwood, Massachusetts facility is the primary site, incorporating automation, robotics and artificial intelligence to increase cost efficiency and reduce waste, with new fill-and-finish capability added in 2027.

The company's own target is a projected 10 percentage point improvement in gross margin over three years from increased volume, manufacturing efficiency and waste reduction. That is a large claim and it is testable against the reported numbers. In the second quarter of 2026, inventory write-downs were $41 million and unutilised manufacturing capacity costs were $23 million against total cost of sales of $93 million — that is, 69% of the cost of the goods actually sold was the cost of goods not sold. Reported gross margin in the quarter was 35.9%. Strip out the write-downs and the idle-capacity charge and the same quarter produces a gross margin of approximately 80%.

The intismeran manufacturing problem is separate and harder. The Marlborough, Massachusetts facility was purpose-built for individualised neoantigen therapy and began clinical batch supply in September 2025. The company describes it as designed for speed and scalability with advanced automation and robotics, on track for commercial launch while it "methodically right-sizes the intismeran manufacturing process to improve turnaround time and reduce costs." The operative word is turnaround. For a personalised therapy the constraint is not annual capacity but cycle time — the interval between tumour resection and infusion — and that interval determines both the clinical usefulness of the product and the working capital it consumes. A 2027 launch with a 12-week turnaround and a 2027 launch with a 6-week turnaround are commercially different products, and the company has not disclosed which it expects.

18 — Policy and reimbursementThe channel, not the science, is the constraint

This section describes the most important and least discussed risk in the equity. Moderna's problem in the United States is not that its products are unapproved. It is that approval and reimbursement are separate gates, and the company currently passes the first and fails the second.

On 16 March 2026 a United States district court, in AAP v. Kennedy, issued a preliminary injunction that stayed all thirteen sitting members of the Advisory Committee on Immunization Practices and invalidated recommendations issued after 11 June 2025. The practical consequence is that no ACIP recommendation issued after that date is in force. That matters far more than it sounds, because the ACIP recommendation is the trigger for several distinct channels: the first-dollar coverage mandate for commercial insurance under the Affordable Care Act, the Vaccines for Children entitlement, and the routine standing of a vaccine in the adult immunisation schedule. Without a recommendation, a vaccine can be approved, licensed, safe and effective, and still not be covered at the pharmacy counter without a co-pay.

The chart above sets out the channel-by-channel position as at our data cut-off, and the pattern is uncomfortable. Product approvals are proceeding normally — VRBPAC voted 9–0 in favour of mRNA-1010 on 18 June 2026 and the FDA approved mFLUSIVA on 5 August 2026, both evidence that the scientific review function is intact. Medicare Part B coverage for influenza vaccines is statutory and therefore not dependent on an ACIP vote, though claims friction remains. But the ACIP recommendation channel is closed, the committee cannot vote, and the two entitlement programmes that depend on a vote are therefore closed with it. In addition, the August 2025 wind-down of BARDA-funded mRNA development programmes removed the public research-funding channel that had supported Moderna's pandemic-response work.

Two qualifications belong next to that. The first is that the injunction is a judicial intervention in an administrative dispute, not a permanent feature of the landscape. It could be lifted, narrowed on appeal, or superseded by legislation, and a restoration of the advisory process would be a material positive catalyst that costs the company nothing. The second is that the international channel is unaffected. The European Commission, the United Kingdom, Canada and Australia have all contracted with Moderna on multi-year terms, and the European joint procurement for mRESVIA was signed on behalf of six countries. Governments outside the United States are behaving as though mRNA vaccines remain a strategic capability. The asymmetry is that the United States is the largest single vaccine market in the world and it is the market where Moderna's position has deteriorated fastest.

19 — Litigation and legal exposureThe $2.25 billion settlement, and the $1.3 billion still open

On 3 March 2026 Moderna entered a global settlement with Genevant Sciences and Arbutus Biopharma to resolve all United States and international enforcement actions relating to its use of lipid nanoparticle delivery technology in its COVID-19 vaccines. The headline number is $2.25 billion. The structure matters more than the headline.

Moderna paid $950 million upfront in July 2026, and it agreed to a further $1.3 billion contingent on an appellate ruling that 28 U.S.C. § 1498 does not bar the claims against it, except as to doses the district court characterised as having gone to United States government employees. In asserting the Section 1498 defence, Moderna argued that the statute applies such that US taxpayers should assume liability for its infringement for sales made under one of its government contracts. That argument is the hinge on which $1.3 billion turns. Moderna also consented to the entry of a judgment of infringement and of no invalidity on the four asserted patents, and Genevant granted it a global non-exclusive licence to its LNP delivery technology for infectious disease applications together with a covenant not to sue.

The settlement is a good outcome in one respect that is easy to miss. It converts an open-ended patent exposure into a defined number and, through the licence and covenant, it removes the risk of an injunction against Spikevax or mRESVIA. For a company whose COVID franchise is already in structural decline, the removal of a tail risk that could have halted US sales entirely is worth more than the headline cost suggests. The comparable exposure at Pfizer/BioNTech remains live — Arbutus and Genevant's litigation against them continues in the United States following a Markman ruling favourable to the patentees in September 2025 — which is a reminder that the LNP patent estate is a genuine constraint on the entire mRNA vaccine industry, not a Moderna-specific problem.

Beyond the LNP litigation, Moderna's disclosed legal matters are of the ordinary commercial-stage kind: patent disputes, product liability and contractual claims, none of which the company treats as material individually. The one structural legal risk worth naming is not a lawsuit at all but a policy risk expressed through litigation — the ACIP injunction described in section 18 is itself the product of a lawsuit, and it demonstrates that the legal system can change a vaccine company's addressable market faster than any clinical trial.

20 — Norovirus and the discontinued programmesWhat failure looks like, in detail

Moderna's pipeline has produced two instructive failures in the last twelve months, and both are worth studying because they show the base rates at work inside a platform company that markets itself on the repeatability of its method.

The first is the cytomegalovirus vaccine, mRNA-1647. On 22 October 2025 the company announced that its Phase 3 pivotal trial did not meet the primary efficacy endpoint of preventing CMV infection. CMV was one of the largest remaining unmet needs in vaccinology, the trial was well powered, and the failure was unambiguous. At its Analyst Day on 20 November 2025 the company discontinued the congenital CMV development programme, retaining only an ongoing Phase 2 trial in bone marrow transplant patients. A platform that had just produced three approved products and a $19 billion peak revenue line could not make a CMV vaccine work.

The second is norovirus. mRNA-1403, the norovirus vaccine candidate, is the most advanced mRNA-platform candidate in Phase 3 and it did not meet the statistical criteria for early success at its interim analysis, disclosed with the second-quarter results in July 2026. The trial remains ongoing and blinded and the company is preparing to enrol an additional cohort, extending the study into a fourth season. A missed interim is not a failed trial — the distinction matters, and the company has framed it correctly — but it does mean that the readout has moved to the right and that the probability of success has fallen. Norovirus was one of the products Moderna identified as a driver of its 2028 seasonal franchise, and the delay pushes it out of the window in which it was supposed to contribute to breakeven.

The pattern across these outcomes is worth stating plainly because it is the analytical bridge to the valuation. Moderna's platform reliably produces candidates that reach the clinic and get to Phase 2 or Phase 3. It does not reliably produce approvals. The respiratory franchise has produced approvals at a good rate — four products in the United States and Europe — while the non-COVID infectious disease pipeline has produced failures at CMV, HSV and VZV. The intismeran programme has just produced the single most valuable clinical result in the company's history. A valuation that capitalises the platform's successes and ignores its failure rate is not a valuation, it is an extrapolation.

21 — Ownership and short interestWho owns the company, and who was betting against it

Moderna's shareholder base is institutional and concentrated in the ordinary way for a large-cap biotechnology company: institutional investors held approximately 75% of the shares, or 323.5 million shares, as of June 2026, with index funds, specialist healthcare funds and generalist growth managers making up the bulk of it. The founder and chief executive retains a meaningful stake, which aligns interests in the usual way and also means that the company has never been a takeover candidate in the conventional sense.

The more informative fact is what happened on the short side. Moderna entered 2026 as one of the most heavily shorted large-cap biotechnology companies in the market, with more than 62 million shares sold short at the start of the year — roughly 16% of the float. The short thesis was coherent and, until August, it was being vindicated: revenue declining, cash burning, a policy environment hostile to the core product, and a breakeven target two years away. By 31 August 2026, short interest had fallen to 39.15 million shares, or 10.99% of the float. On any measure that remains a heavily shorted stock, but it is a 37% reduction from the peak.

The chart above plots short interest against the share price and it tells the story of the August re-rating more accurately than any narrative account. Short interest declined steadily through the first half, from 62.4 million shares in March to 48.6 million in July, while the price moved from $27.60 to $31.80. Then, in August, the price went from $31.80 to $128.40 while short interest fell from 48.6 million to 39.2 million — a reduction of 9.4 million shares against a float of roughly 356 million. Nine million shares of covering demand cannot by itself move a $13 billion company to $73 billion. What it can do is remove the marginal seller at exactly the moment when the marginal buyer arrives, and in a thin market that is enough to produce a price that is not an equilibrium.

One further observation about ownership deserves a place here, because it bears on the valuation. The analyst community has not followed the price. Across 23 covering analysts the average rating is Hold and the average twelve-month target is $119.56, which is 34.5% below the 22 September close. Targets have risen — Rothschild & Co Redburn raised its target from $40 to $81 on 3 September 2026 even as it downgraded the shares from Neutral to Sell — but they have not risen remotely to the level of the price, and the dispersion across data providers has widened rather than narrowed. Consensus targets for the stock now cluster in a range of roughly $106 to $125 depending on the provider and the coverage set. When the price and the professional estimates diverge by a third, one of them is wrong, and the burden of proof belongs to whoever is asserting the higher number.

22 — Valuation frameworkWhy the multiples do not work, and what we use instead

Moderna is close to unvaluable by conventional means, and it is worth being explicit about why before proposing an alternative. A price-to-earnings approach is unavailable because there are no earnings and none are forecast. An EV/EBITDA approach is unavailable for the same reason. A price-to-sales approach is available but close to meaningless, because the revenue base is in structural decline, has no comparable growth profile, and is composed of a shrinking annuity plus a set of products that have not yet been launched. A discounted-cash-flow approach requires a terminal revenue and margin assumption that is doing all the work and is unverifiable.

What is left is a sum-of-parts valuation in which each asset is valued on its own terms. That is the right approach for a company that is genuinely a portfolio of programmes at different stages of maturity, and it has the considerable virtue of being auditable: every number in the model can be traced to a programme, a probability and a discount rate, and a reader who disagrees with the answer can identify exactly which assumption they disagree with.

The four inputs

Discount rate: 11%. We use a single rate across the portfolio rather than a programme-specific one, on the grounds that Moderna's cost of equity is a company-level variable and the differentiation belongs in the probability of success. Eleven per cent is above the market average and reflects a pre-profit, single-technology company with a concentrated pipeline and a policy-exposed revenue base. Readers who think a validated oncology platform deserves a lower rate will get a higher valuation than ours; the sensitivity is roughly $4 billion of value per percentage point across a portfolio with this duration profile.

Probability of success: programme-specific. This is where most of the analytical content sits. We use 78% for intismeran autogene, which is high by the standards of oncology development but is conditional on the Phase 3 having already read out positively and on the regulatory path being clear. We use 95% for the influenza and combination franchise, because mFLUSIVA is approved and the remaining risk is commercial rather than clinical. We use 85% for the COVID franchise, where the risk is not approval but volume. We use 30% for norovirus, reflecting a missed interim in a Phase 3 that is still blinded. We use 12–20% for the Horizon 2 and Horizon 3 modalities, which is roughly the historical base rate for Phase 1 oncology programmes. We use 60% for the rare disease programmes, reflecting a fully enrolled registrational study in a population with no approved therapy.

Revenue and margin assumptions. For each programme we model a peak revenue and a launch date, then apply a margin appropriate to the product's economics and a programme-specific ramp. For intismeran we apply the 50/50 cost and profit share with Merck, which means only half of the modelled franchise value accrues to Moderna. This single assumption removes roughly $12 billion of value from the sum of parts relative to a naive calculation, and it is the assumption most often omitted in published bull cases.

Net cash: $5.4 billion. Cash, cash equivalents and investments of $6.9 billion at 30 June 2026, less the $950 million settlement paid in July 2026, less $591 million of long-term debt. We use the post-settlement figure rather than the more flattering pre-settlement one, for the reasons set out in section 15.

23 — Risk-adjusted valueThe company, priced programme by programme

The table below is the full sum of parts. Every figure in it is a model output, and the derivations are stated so that a reader can disagree with a specific input rather than with the conclusion.

The distribution of value inside that table is the most important thing in this report. Two assets — intismeran and COVID — account for 55% of the risk-adjusted value, and adding net cash takes the top three to 70%. Everything else the company owns, including four approved products, three of them launched into the largest vaccine markets in the world, is worth approximately $10.3 billion in total. Intismeran alone is 36% of the sum of parts, and 42% if net cash is excluded. This is not a diversified vaccine company with an oncology option. It is an oncology option with a vaccine business attached, and the market is pricing the option while the vaccine business shrinks beneath it.

The bridge above is the central exhibit of the report. The risk-adjusted sum of parts is $34.9 billion. The market capitalisation is $72.9 billion. The gap is $38.0 billion, or 109%. Per share, our risk-adjusted value is $87 against a price of $182.56, so the shares trade at 2.1 times the risk-adjusted value of everything the company owns.

Two caveats belong next to that conclusion, and they cut in opposite directions. The first is that a sum-of-parts model systematically understates the value of a platform whose option value is real but unquantifiable. If the intismeran result genuinely validates individualised neoantigen therapy as a modality, the correct way to value the programme is not a peak-revenue estimate for the indications currently in trials but a share of the entire adjuvant oncology market over the next twenty years. Our $8.2 billion bull case is a deliberately constrained number, and a reader who believes the modality generalises fully will legitimately arrive at a value several times higher. The second caveat is that a sum-of-parts model also systematically overstates the value of optionality in a company with a halved research budget. Options that cannot be exercised at scale are not worth what a textbook would say they are worth, and Moderna has just halved the budget.

24 — Scenario analysisThree stories, one probability-weighted answer

A single-point estimate is the wrong output for an equity like this. The distribution is wide, the outcomes are driven by a small number of discrete events, and the difference between the cases is the difference between a company that works and a company that does not. We therefore present three cases and weight them.

The bear case is not a story about failure. It is a story about a company that is scientifically successful and commercially unlucky. Intismeran is approved but launches into a reimbursement environment with no precedent for a six-figure personalised adjuvant therapy, the manufacturing ramp is capacity-constrained, and the product reaches $1.0 billion of gross revenue by 2033 rather than $3.9 billion. The respiratory business flatlines because the reimbursement channel stays closed and the international contracts do not scale. Norovirus fails. The Section 1498 appeal is lost and $1.3 billion leaves the balance sheet. Cash costs stay at the top of the guided range and the company raises equity in 2029 at a price the market sets. On those assumptions the risk-adjusted value is approximately $8.4 billion, or $21 per share — 88% below the current price.

The base case is the case described throughout this report. Intismeran launches in 2027, reaches $3.9 billion of gross revenue by 2033, and generates $12.4 billion of risk-adjusted value to Moderna after the Merck share. Respiratory revenue compounds at 18% a year from the 2026 base, driven by mNEXSPIKE uptake, the flu-plus-COVID combination and international contracts rather than by a US recovery. Cash costs land at the mid-point of the guided 2027 range and cash breakeven is reached in 2028. On those assumptions the fair value is $87.50 per share — 52% below the current price.

The bull case requires the modality to generalise and the market to recognise it. Intismeran becomes an $8.2 billion franchise by 2033 as the adjuvant NSCLC, bladder and renal cell indications read out positively and reimbursement is established. Respiratory revenue compounds at 30% a year as the combination product takes share from incumbent adjuvanted products in the 65-plus segment. Norovirus launches in 2028 and adds a new seasonal product. The Horizon 2 modalities are validated, the in vivo CAR-T programme reaches the clinic with encouraging data, and the platform is re-rated as a modality rather than as a product. Cash costs land at the low end of guidance and breakeven is reached a year early. On those assumptions the fair value is $214 per share — 17% above the current price.

The scenario probabilities are illustrative and not measured, which is a limitation we accept rather than disguise. What we can say with more confidence is that the market price sits between the base and the bull cases and closer to the bull case than to the base. At $182.56 the shares are priced for an outcome that requires both the modality to generalise and the commercial execution to be competent, with no allowance for the possibility that the reimbursement environment remains closed, that the personalised manufacturing ramp is slow, or that the balance sheet is diluted before the revenue arrives. That is not a forecast of failure. It is an observation that the price has stopped distinguishing between the good case and the certain case.

25 — The bull caseStated at full strength

The strongest version of the bull case does not rest on the share price, on momentum, or on the squeeze. It rests on a single proposition: that on 19 August 2026 an entire class of medicine moved from hypothesis to demonstrated fact, and that the company which demonstrated it is trading at a valuation that does not yet reflect how large that class of medicine is.

That proposition is serious, and it deserves to be argued properly. Individualised neoantigen therapy has been the most attractive idea in oncology for a decade and the most disappointing in practice. Every previous attempt has failed on one of three rocks: the neoantigen prediction algorithms were not good enough to select targets that a T-cell could act on; the manufacturing was too slow and too expensive to be commercially viable at scale; or the clinical effect, when it appeared, was too small to detect against a modern standard of care. INTerpath-001 says that at least in adjuvant melanoma, none of those three rocks is fatal. The algorithm picked targets that worked. The manufacturing delivered. The effect was large enough to meet a Phase 3 primary endpoint at an interim against KEYTRUDA.

If that is true, then the relevant question is not what intismeran is worth in melanoma. It is what share of the adjuvant oncology market a validated personalised neoantigen platform can capture over the next twenty years. Adjuvant therapy is the single most valuable setting in oncology, because it treats patients who are curable and can therefore justify high prices and long treatment durations. Moderna has nine trials running across four tumour types and three Phase 3 programmes. Each positive readout adds an indication; each added indication compounds the value of a manufacturing platform whose fixed costs are already sunk. That is a genuinely convex payoff, and convexity is worth paying for.

The bull case also has a second leg that the market has largely ignored, which is the combination vaccine franchise. The company's own framing at its Analyst Day was to build a large seasonal vaccine franchise for at-risk populations and use the cash it generates to fund oncology and rare disease. That is the correct strategy for a company in Moderna's position: a flu-plus-COVID combination product, if it takes share from incumbent adjuvanted products in the 65-plus segment, is a high-margin annuity with a five-year replacement cycle and no clinical risk remaining. mCOMBRIAX is already authorised in Europe. The US refiling is a matter of FDA guidance rather than of data. A combination franchise worth $2 billion of annual revenue would transform the cash flow statement and would make the 2028 breakeven target an unremarkable outcome rather than an ambitious one.

There is a version of the bull case that goes further, and it should be acknowledged even though we do not adopt it. If the intismeran result is the beginning of a generalisable modality rather than a single successful product, then a risk-adjusted net present value is the wrong valuation tool entirely, because it discounts optionality that has not yet been created. The correct tool would be a share of a total addressable market measured in the tens of billions, applied with a probability that rises with every readout. On that construction the shares are worth several hundred dollars. We do not adopt it because it requires assumptions about indications that have not reported, a manufacturing scale that has not been demonstrated, and a reimbursement environment that does not yet exist. But it is not an unreasonable view, and any investor who holds it should hold it knowingly rather than accidentally.

26 — The bear caseStated at full strength

The bear case does not require Moderna's science to fail. It requires only that the science succeed and the business not. That is a much less demanding set of assumptions, and it is where the asymmetry in this equity actually sits.

Start with the revenue base. Total revenue has fallen from $19.26 billion in 2022 to an estimated $2.10 billion in 2026 — a decline of 89% — and the company's own guidance for 2026 is growth of up to 10%, which is the language of stabilisation rather than of recovery. The COVID franchise is now smaller than the annual research budget and continues to decline. The three non-COVID products generate a small minority of revenue. The company has guided 2027 cash costs to $3.5–3.9 billion, and reaching cash breakeven in 2028 on those costs requires revenue growth of roughly 33% a year for two years, against a base that has been shrinking for four. The bear case is not that this is impossible. It is that it is being treated as certain.

Then add the policy position. The ACIP recommendation channel has been closed since 16 March 2026 by a preliminary injunction that stayed all thirteen committee members and invalidated every recommendation issued after 11 June 2025. That closes the first-dollar commercial coverage mandate, the Vaccines for Children entitlement, and the routine standing of any vaccine in the adult schedule. Moderna's products can be approved and still not be covered. Every new launch — mFLUSIVA, mCOMBRIAX, any future product — enters a market where the mechanism that converts an approval into routine use is under a court order. The company cannot fix this with better science, and there is no date by which it is resolved.

Then add the balance sheet. $4.8 billion of guided year-end cash against an underlying annual cash cost base of approximately $4.7 billion is roughly one year of operating expense in liquid form. Our bear case exhausts liquidity in 2029 with no equity issuance. And there is a discrete $1.3 billion contingent payment hanging over the balance sheet that becomes payable if the Section 1498 appeal is lost — 27% of the guided year-end cash balance, in a single payment, at a moment of the court's choosing.

Finally, add the intismeran execution risk, which is the risk the price is least prepared for. A personalised therapy requires a dedicated batch for every patient within a clinically useful window. Moderna's Marlborough facility is described as being on track for commercial launch while the company "methodically right-sizes the intismeran manufacturing process to improve turnaround time and reduce costs." That is the language of a process that is not yet settled. If the ramp is capacity-constrained, revenue is governed by throughput rather than demand, and the 2027 launch slips into a slower trajectory than any model assumes. And if reimbursement for a six-figure personalised adjuvant therapy takes two years to establish — which is not a pessimistic assumption given that no precedent exists — then the revenue arrives after the cash has gone.

The bear case has one clear weakness, and it is worth stating because it is the reason we do not weight it above 25%. It requires the company to fail at everything simultaneously. The respiratory franchise would have to decline rather than stabilise; intismeran would have to be both late and poorly reimbursed; norovirus would have to fail outright; the appeal would have to be lost; and the balance sheet would have to be diluted. Each of those is plausible individually. Their conjunction is not the most likely state of the world, and a bear case built on conjunction is a bear case that will usually be wrong. That is why it carries a 25% weight rather than a 50% one.

27 — Risk matrixThe register, and where the risks sit

The table below is the full risk register, rated for probability and impact on a one-to-five scale. The heat map that follows plots the same twelve risks against both dimensions, so a reader can see at a glance where the concentration sits.

Cells read left to right as impact rises from 1 to 5, top to bottom as probability rises from 1 to 5. Superscripts identify risks from the register above. The mass of the register sits in the P3–P4 rows at impact 4 and 5, which is the analytical expression of the central problem: the risks are not unlikely, and they are not small.

28 — CatalystsWhat we are watching, and when

29 — ConclusionA validated modality, priced as a completed one

The uncomfortable conclusion of this report is that the most interesting thing about Moderna is also the least investable thing about it. The INTerpath-001 result is a genuine scientific achievement, and we have said so throughout. It converts individualised neoantigen therapy from a hypothesis into a demonstrated fact, in a disease where the incumbent standard of care is one of the most successful drugs ever developed, and it was produced by a company whose platform was widely written off eighteen months ago. Anyone who dismissed Moderna as a pandemic one-trick company was wrong, and the eightfold move in the shares is a fair correction of that error.

But a validated modality is not a commercial franchise, and the distance between the two is where the investment case lives. The company's revenue has fallen 89% from its peak and is guided to grow by at most 10%. Its commercial base is now majority-international at exactly the moment its most valuable asset will be launched in the United States first. The reimbursement channel that converts an approval into routine use has been closed by injunction since March 2026, and every new product — including the one that is supposed to fund the company — must enter through it. The balance sheet holds roughly one year of operating expense in liquid form, and a $1.3 billion contingent liability sits outside it. And the breakeven commitment for 2028 requires revenue growth of roughly 33% a year from a base that has been declining for four years.

None of that is a reason to doubt the science. All of it is a reason to doubt that the price has left anything on the table. At 29.9 times trailing revenue against a comparable-company median of 4.4 times, and at 2.1 times our risk-adjusted sum of parts, the equity has already paid for the achievement several times over and has begun to pay for achievements that have not happened. Even our bull case, in which the modality generalises, the combination franchise takes share, norovirus works, the appeal is won and the platform is re-rated, gets to $214 — 17% above the current price. When the good case is barely above the price and the bad case is 88% below it, the distribution is not symmetric in the direction the price implies.

We are therefore Underweight, with a $110 twelve-month target. We are explicitly not arguing that Moderna is a broken company, that its science is unimpressive, or that the August result was anything other than a major achievement. We are arguing that the equity has already paid for the achievement several times over, that the commercial base beneath it is shrinking, that the reimbursement channel for new products is closed by litigation rather than by science, and that the company's own breakeven commitment implies a revenue trajectory its four approved products are not currently producing. Those four observations are not a forecast. They are the current filing.

30 — Appendix: financialsThe numbers behind the report

Per-share figures are calculated on 399.24 million shares outstanding as at 22 September 2026. Base-case influenza, combination and RSV of $5.5 billion equals the $3.9 billion influenza and combination component plus the $1.6 billion RSV component shown separately in the section 23 table. Bear-case net cash reflects the $1.3 billion contingency being paid and the balance sheet being diluted.

31 — SourcesPrimary and secondary references

Primary company filings and disclosures

• Moderna, Inc., Second Quarter 2026 Financial Results and Business Updates, 31 July 2026.
• Moderna, Inc., First Quarter 2026 Financial Results, 2026.
• Moderna, Inc., Fourth Quarter and Full Year 2025 Financial Results, 13 February 2026.
• Moderna, Inc., Analyst Day: three-year business strategy and commercial growth drivers, 20 November 2025, and the accompanying Form 8-K exhibit.
• Moderna, Inc., Business and pipeline updates at the 44th Annual J.P. Morgan Healthcare Conference, 12 January 2026.
• Moderna, Inc., Science Day: expanding potential of the mRNA platform, 25 June 2026.
• Moderna, Inc., Phase 3 study of investigational cytomegalovirus vaccine did not meet primary efficacy endpoint, 22 October 2025.
• Moderna, Inc. and Merck & Co., INTerpath-001 Phase 3 topline results for intismeran autogene plus KEYTRUDA, 19 August 2026.
• Moderna, Inc. and Merck & Co., Five-year Phase 2b KEYNOTE-942 data at the ASCO 2026 annual meeting, 1 June 2026.
• Moderna, Inc., FDA approval of mFLUSIVA for seasonal influenza in adults aged 50 and over, 5 August 2026.
• Moderna, Inc., Resolves global patent litigation with Arbutus/Genevant, 3 March 2026, and the related Form 8-K.
• Moderna, Inc., Form 10-Q for the quarter ended 30 June 2026; Form 10-K for the fiscal year ended 31 December 2025.

Counterparty, regulatory and legal sources

• Genevant Sciences and Arbutus Biopharma, $2.25 billion global settlement with Moderna, 3 March 2026, and Arbutus Form 8-K of the same date.
• United States District Court for the District of Massachusetts, American Academy of Pediatrics v. Kennedy, preliminary injunction of 16 March 2026 staying ACIP members and invalidating recommendations issued after 11 June 2025.
• US Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee, unanimous recommendation on mRNA-1010, 18 June 2026.
• Coalition for Epidemic Preparedness Innovations, investment of up to $54.3 million in the mRNA-1018 H5 pandemic influenza programme, 12 January 2026.
• Ares Management Credit Funds, five-year term loan facility of up to $1.5 billion, closed November 2025.
• European Commission joint procurement contract for up to 24 million doses of mRESVIA on behalf of six countries, 2026.
• ClinicalTrials.gov registrations for INTerpath-001, P304 (NCT06602024), mRNA-1403 (NCT05992935) and mRNA-3927 (NCT04159103).

Market data and third-party research

• Share price, market capitalisation, share count and valuation multiples as at the close on 22 September 2026.
• Exchange-reported short interest settlement data for the period to 31 August 2026, as compiled by third-party data providers.
• Consensus ratings, price targets and coverage counts as compiled by third-party market data aggregators, September 2026.
• Rothschild & Co Redburn, downgrade to Sell with a $81 price target, 3 September 2026.
• Institutional ownership data as compiled from Form 13F filings for the period to 30 June 2026.
• Phase 3 P304 results as published in the New England Journal of Medicine; Phase 1/2 mRNA-3927 interim results as published in Nature, 2024.

32 — DisclosureConflicts, limitations, and revision policy